Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial

BACKGROUND: Although platinum-based chemotherapy is accepted as adjuvant chemotherapy for resectable advanced non-small cell lung cancer (NSCLC), its completion rate is low due to severe adverse events. S-1 plus cisplatin is associated with relatively low toxicity and an unimpaired quality of life,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Thorac Dis
Autori principali: Uematsu, Shugo, Sano, Atsushi, Isobe, Kazutoshi, Usui, Kazuhiro, Matsumoto, Jun, Kiribayashi, Takaharu, Obara, Kiyohaya, Kitami, Akihiko, Murakami, Yoshitaka, Iyoda, Akira
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2021
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107543/
https://ncbi.nlm.nih.gov/pubmed/34012573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-20-3293
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi